nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—ABCG2—hematologic cancer	0.143	0.706	CbGaD
Buprenorphine—ABCB1—hematologic cancer	0.0594	0.294	CbGaD
Buprenorphine—CYP2C18—Ifosfamide—hematologic cancer	0.0202	0.038	CbGbCtD
Buprenorphine—ABCG2—Clofarabine—hematologic cancer	0.0193	0.0364	CbGbCtD
Buprenorphine—CYP2A6—Methoxsalen—hematologic cancer	0.0134	0.0253	CbGbCtD
Buprenorphine—UGT1A9—Irinotecan—hematologic cancer	0.012	0.0227	CbGbCtD
Buprenorphine—CYP1A2—Anagrelide—hematologic cancer	0.0115	0.0217	CbGbCtD
Buprenorphine—ABCG2—Daunorubicin—hematologic cancer	0.0113	0.0213	CbGbCtD
Buprenorphine—ABCG2—Teniposide—hematologic cancer	0.00984	0.0185	CbGbCtD
Buprenorphine—CYP2A6—Ifosfamide—hematologic cancer	0.00981	0.0185	CbGbCtD
Buprenorphine—ABCG2—Cladribine—hematologic cancer	0.00943	0.0178	CbGbCtD
Buprenorphine—ABCG2—Imatinib—hematologic cancer	0.00867	0.0163	CbGbCtD
Buprenorphine—ABCG2—Nilotinib—hematologic cancer	0.00788	0.0149	CbGbCtD
Buprenorphine—CYP2C9—Bexarotene—hematologic cancer	0.00717	0.0135	CbGbCtD
Buprenorphine—ABCG2—Dasatinib—hematologic cancer	0.00696	0.0131	CbGbCtD
Buprenorphine—ABCB1—Lenalidomide—hematologic cancer	0.00696	0.0131	CbGbCtD
Buprenorphine—ABCG2—Mitoxantrone—hematologic cancer	0.00688	0.013	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.0067	0.0126	CbGbCtD
Buprenorphine—CYP3A7—Ifosfamide—hematologic cancer	0.0067	0.0126	CbGbCtD
Buprenorphine—CYP2A6—Prednisolone—hematologic cancer	0.00654	0.0123	CbGbCtD
Buprenorphine—CYP3A7—Imatinib—hematologic cancer	0.0064	0.0121	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.0064	0.0121	CbGbCtD
Buprenorphine—CYP2C8—Bortezomib—hematologic cancer	0.0063	0.0119	CbGbCtD
Buprenorphine—CYP3A5—Daunorubicin—hematologic cancer	0.00627	0.0118	CbGbCtD
Buprenorphine—CYP2D6—Lomustine—hematologic cancer	0.0061	0.0115	CbGbCtD
Buprenorphine—CYP1A2—Carmustine—hematologic cancer	0.00603	0.0114	CbGbCtD
Buprenorphine—CYP2C9—Idarubicin—hematologic cancer	0.00594	0.0112	CbGbCtD
Buprenorphine—CYP3A5—Thalidomide—hematologic cancer	0.00571	0.0108	CbGbCtD
Buprenorphine—CYP3A5—Teniposide—hematologic cancer	0.00545	0.0103	CbGbCtD
Buprenorphine—CYP2D6—Idarubicin—hematologic cancer	0.00544	0.0102	CbGbCtD
Buprenorphine—ABCG2—Irinotecan—hematologic cancer	0.00542	0.0102	CbGbCtD
Buprenorphine—CYP2C19—Bortezomib—hematologic cancer	0.00529	0.00997	CbGbCtD
Buprenorphine—CYP1A2—Methoxsalen—hematologic cancer	0.00513	0.00967	CbGbCtD
Buprenorphine—CYP3A5—Ifosfamide—hematologic cancer	0.00503	0.00948	CbGbCtD
Buprenorphine—CYP1A2—Bortezomib—hematologic cancer	0.00488	0.0092	CbGbCtD
Buprenorphine—CYP2C8—Ifosfamide—hematologic cancer	0.00484	0.00912	CbGbCtD
Buprenorphine—CYP3A5—Imatinib—hematologic cancer	0.0048	0.00906	CbGbCtD
Buprenorphine—ABCG2—Vincristine—hematologic cancer	0.00473	0.00892	CbGbCtD
Buprenorphine—CYP1A2—Daunorubicin—hematologic cancer	0.00467	0.0088	CbGbCtD
Buprenorphine—CYP2D6—Hydroxyurea—hematologic cancer	0.00462	0.00871	CbGbCtD
Buprenorphine—CYP2C19—Thalidomide—hematologic cancer	0.00461	0.00869	CbGbCtD
Buprenorphine—CYP1A2—Alitretinoin—hematologic cancer	0.00457	0.00862	CbGbCtD
Buprenorphine—ABCG2—Cisplatin—hematologic cancer	0.00442	0.00832	CbGbCtD
Buprenorphine—CYP2C9—Bortezomib—hematologic cancer	0.0044	0.00829	CbGbCtD
Buprenorphine—CYP2C19—Teniposide—hematologic cancer	0.0044	0.00829	CbGbCtD
Buprenorphine—ABCG2—Etoposide—hematologic cancer	0.00434	0.00818	CbGbCtD
Buprenorphine—CYP1A2—Thalidomide—hematologic cancer	0.00425	0.00801	CbGbCtD
Buprenorphine—CYP2C8—Nilotinib—hematologic cancer	0.0042	0.00791	CbGbCtD
Buprenorphine—CYP3A4—Bexarotene—hematologic cancer	0.00417	0.00786	CbGbCtD
Buprenorphine—ABCB1—Daunorubicin—hematologic cancer	0.00408	0.00769	CbGbCtD
Buprenorphine—CYP2C19—Ifosfamide—hematologic cancer	0.00406	0.00765	CbGbCtD
Buprenorphine—CYP2D6—Bortezomib—hematologic cancer	0.00402	0.00758	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.004	0.00754	CbGbCtD
Buprenorphine—CYP3A7—Irinotecan—hematologic cancer	0.004	0.00754	CbGbCtD
Buprenorphine—ABCB1—Alitretinoin—hematologic cancer	0.004	0.00754	CbGbCtD
Buprenorphine—CYP3A4—Busulfan—hematologic cancer	0.00388	0.00731	CbGbCtD
Buprenorphine—CYP3A4—Lomustine—hematologic cancer	0.00388	0.00731	CbGbCtD
Buprenorphine—CYP2C19—Imatinib—hematologic cancer	0.00388	0.0073	CbGbCtD
Buprenorphine—CYP3A5—Dasatinib—hematologic cancer	0.00386	0.00727	CbGbCtD
Buprenorphine—CYP2A6—Dexamethasone—hematologic cancer	0.00385	0.00726	CbGbCtD
Buprenorphine—CYP2C9—Thalidomide—hematologic cancer	0.00383	0.00722	CbGbCtD
Buprenorphine—CYP1A2—Dacarbazine—hematologic cancer	0.00366	0.00689	CbGbCtD
Buprenorphine—CYP2C9—Teniposide—hematologic cancer	0.00365	0.00689	CbGbCtD
Buprenorphine—CYP1A2—Imatinib—hematologic cancer	0.00358	0.00674	CbGbCtD
Buprenorphine—ABCG2—Dexamethasone—hematologic cancer	0.00357	0.00672	CbGbCtD
Buprenorphine—CYP3A7—Vincristine—hematologic cancer	0.0035	0.00659	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.0035	0.00659	CbGbCtD
Buprenorphine—CYP3A4—Thiotepa—hematologic cancer	0.00346	0.00652	CbGbCtD
Buprenorphine—CYP2C9—Ifosfamide—hematologic cancer	0.00337	0.00636	CbGbCtD
Buprenorphine—CYP2C9—Imatinib—hematologic cancer	0.00322	0.00607	CbGbCtD
Buprenorphine—ABCB1—Imatinib—hematologic cancer	0.00313	0.00589	CbGbCtD
Buprenorphine—CYP3A5—Irinotecan—hematologic cancer	0.003	0.00566	CbGbCtD
Buprenorphine—ABCG2—Doxorubicin—hematologic cancer	0.00296	0.00558	CbGbCtD
Buprenorphine—CYP2D6—Imatinib—hematologic cancer	0.00295	0.00555	CbGbCtD
Buprenorphine—CYP2C9—Nilotinib—hematologic cancer	0.00293	0.00552	CbGbCtD
Buprenorphine—CYP1A2—Dasatinib—hematologic cancer	0.00287	0.00541	CbGbCtD
Buprenorphine—ABCG2—Methotrexate—hematologic cancer	0.00287	0.0054	CbGbCtD
Buprenorphine—ABCB1—Nilotinib—hematologic cancer	0.00284	0.00536	CbGbCtD
Buprenorphine—ABCB1—Vinorelbine—hematologic cancer	0.00282	0.00531	CbGbCtD
Buprenorphine—CYP3A4—Methoxsalen—hematologic cancer	0.00269	0.00507	CbGbCtD
Buprenorphine—CYP2D6—Nilotinib—hematologic cancer	0.00268	0.00505	CbGbCtD
Buprenorphine—CYP2D6—Vinorelbine—hematologic cancer	0.00265	0.005	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00263	0.00497	CbGbCtD
Buprenorphine—CYP3A7—Dexamethasone—hematologic cancer	0.00263	0.00497	CbGbCtD
Buprenorphine—CYP3A5—Vincristine—hematologic cancer	0.00262	0.00494	CbGbCtD
Buprenorphine—CYP3A4—Bortezomib—hematologic cancer	0.00256	0.00482	CbGbCtD
Buprenorphine—CYP2C19—Prednisone—hematologic cancer	0.00255	0.00481	CbGbCtD
Buprenorphine—ABCB1—Dasatinib—hematologic cancer	0.00251	0.00473	CbGbCtD
Buprenorphine—ABCB1—Mitoxantrone—hematologic cancer	0.00248	0.00468	CbGbCtD
Buprenorphine—CYP3A4—Daunorubicin—hematologic cancer	0.00245	0.00461	CbGbCtD
Buprenorphine—CYP3A5—Etoposide—hematologic cancer	0.0024	0.00453	CbGbCtD
Buprenorphine—CYP2C8—Etoposide—hematologic cancer	0.00231	0.00436	CbGbCtD
Buprenorphine—ABCB1—Betamethasone—hematologic cancer	0.00221	0.00417	CbGbCtD
Buprenorphine—ABCB1—Gemcitabine—hematologic cancer	0.00219	0.00413	CbGbCtD
Buprenorphine—ABCB1—Prednisolone—hematologic cancer	0.00218	0.00411	CbGbCtD
Buprenorphine—CYP3A4—Cytarabine—hematologic cancer	0.00216	0.00407	CbGbCtD
Buprenorphine—CYP3A4—Teniposide—hematologic cancer	0.00212	0.00401	CbGbCtD
Buprenorphine—ABCB1—Prednisone—hematologic cancer	0.00206	0.00388	CbGbCtD
Buprenorphine—CYP3A5—Dexamethasone—hematologic cancer	0.00198	0.00372	CbGbCtD
Buprenorphine—CYP3A4—Ifosfamide—hematologic cancer	0.00196	0.0037	CbGbCtD
Buprenorphine—ABCB1—Irinotecan—hematologic cancer	0.00195	0.00368	CbGbCtD
Buprenorphine—CYP2C8—Dexamethasone—hematologic cancer	0.0019	0.00358	CbGbCtD
Buprenorphine—OPRL1—hematopoietic system—hematologic cancer	0.0019	0.138	CbGeAlD
Buprenorphine—CYP3A4—Imatinib—hematologic cancer	0.00187	0.00353	CbGbCtD
Buprenorphine—CYP1A2—Etoposide—hematologic cancer	0.00179	0.00337	CbGbCtD
Buprenorphine—CYP3A4—Ruxolitinib—hematologic cancer	0.00176	0.00333	CbGbCtD
Buprenorphine—ABCB1—Vinblastine—hematologic cancer	0.00174	0.00327	CbGbCtD
Buprenorphine—ABCB1—Vincristine—hematologic cancer	0.00171	0.00322	CbGbCtD
Buprenorphine—CYP3A4—Nilotinib—hematologic cancer	0.0017	0.00321	CbGbCtD
Buprenorphine—CYP3A4—Vinorelbine—hematologic cancer	0.00169	0.00318	CbGbCtD
Buprenorphine—CYP2C9—Cisplatin—hematologic cancer	0.00164	0.00309	CbGbCtD
Buprenorphine—CYP2D6—Vinblastine—hematologic cancer	0.00164	0.00308	CbGbCtD
Buprenorphine—CYP2C19—Dexamethasone—hematologic cancer	0.00159	0.003	CbGbCtD
Buprenorphine—ABCB1—Cisplatin—hematologic cancer	0.00159	0.003	CbGbCtD
Buprenorphine—ABCB1—Etoposide—hematologic cancer	0.00156	0.00295	CbGbCtD
Buprenorphine—CYP3A4—Triamcinolone—hematologic cancer	0.00154	0.00291	CbGbCtD
Buprenorphine—CYP3A4—Dasatinib—hematologic cancer	0.0015	0.00284	CbGbCtD
Buprenorphine—CYP3A4—Mitoxantrone—hematologic cancer	0.00149	0.0028	CbGbCtD
Buprenorphine—CYP2C9—Dexamethasone—hematologic cancer	0.00133	0.0025	CbGbCtD
Buprenorphine—CYP3A4—Betamethasone—hematologic cancer	0.00132	0.0025	CbGbCtD
Buprenorphine—CYP3A4—Prednisolone—hematologic cancer	0.00131	0.00246	CbGbCtD
Buprenorphine—ABCB1—Dexamethasone—hematologic cancer	0.00129	0.00242	CbGbCtD
Buprenorphine—OPRL1—blood—hematologic cancer	0.00126	0.0914	CbGeAlD
Buprenorphine—CYP3A4—Prednisone—hematologic cancer	0.00123	0.00233	CbGbCtD
Buprenorphine—Naloxone—CREB1—hematologic cancer	0.00122	0.51	CrCbGaD
Buprenorphine—CYP2D6—Dexamethasone—hematologic cancer	0.00121	0.00228	CbGbCtD
Buprenorphine—CYP3A4—Irinotecan—hematologic cancer	0.00117	0.00221	CbGbCtD
Buprenorphine—ABCB1—Doxorubicin—hematologic cancer	0.00107	0.00201	CbGbCtD
Buprenorphine—CYP3A4—Vinblastine—hematologic cancer	0.00104	0.00196	CbGbCtD
Buprenorphine—OPRL1—testis—hematologic cancer	0.00104	0.0756	CbGeAlD
Buprenorphine—ABCB1—Methotrexate—hematologic cancer	0.00103	0.00195	CbGbCtD
Buprenorphine—CYP3A4—Vincristine—hematologic cancer	0.00102	0.00193	CbGbCtD
Buprenorphine—CYP2D6—Doxorubicin—hematologic cancer	0.00101	0.00189	CbGbCtD
Buprenorphine—CYP3A4—Etoposide—hematologic cancer	0.000937	0.00177	CbGbCtD
Buprenorphine—CYP3A4—Dexamethasone—hematologic cancer	0.000771	0.00145	CbGbCtD
Buprenorphine—OPRL1—lymph node—hematologic cancer	0.000753	0.0548	CbGeAlD
Buprenorphine—OPRM1—hematopoietic system—hematologic cancer	0.000666	0.0484	CbGeAlD
Buprenorphine—CYP3A4—Doxorubicin—hematologic cancer	0.000639	0.0012	CbGbCtD
Buprenorphine—Naltrexone—UGT1A1—hematologic cancer	0.00059	0.247	CrCbGaD
Buprenorphine—CYP2C19—hematopoietic system—hematologic cancer	0.000459	0.0334	CbGeAlD
Buprenorphine—OPRM1—blood—hematologic cancer	0.000441	0.0321	CbGeAlD
Buprenorphine—CYP2A6—lung—hematologic cancer	0.000414	0.0301	CbGeAlD
Buprenorphine—CYP2C8—hematopoietic system—hematologic cancer	0.000401	0.0291	CbGeAlD
Buprenorphine—CYP1A2—hematopoietic system—hematologic cancer	0.000375	0.0273	CbGeAlD
Buprenorphine—OPRM1—testis—hematologic cancer	0.000365	0.0265	CbGeAlD
Buprenorphine—CYP3A5—hematopoietic system—hematologic cancer	0.000361	0.0263	CbGeAlD
Buprenorphine—CYP2C9—hematopoietic system—hematologic cancer	0.000356	0.0259	CbGeAlD
Buprenorphine—CYP2C19—blood—hematologic cancer	0.000304	0.0221	CbGeAlD
Buprenorphine—CYP3A4—hematopoietic system—hematologic cancer	0.000271	0.0197	CbGeAlD
Buprenorphine—CYP2D6—hematopoietic system—hematologic cancer	0.000267	0.0194	CbGeAlD
Buprenorphine—CYP2C8—blood—hematologic cancer	0.000265	0.0193	CbGeAlD
Buprenorphine—ABCG2—blood—hematologic cancer	0.000258	0.0188	CbGeAlD
Buprenorphine—ABCG2—bone marrow—hematologic cancer	0.00025	0.0182	CbGeAlD
Buprenorphine—CYP1A2—blood—hematologic cancer	0.000248	0.0181	CbGeAlD
Buprenorphine—CYP3A5—blood—hematologic cancer	0.000239	0.0174	CbGeAlD
Buprenorphine—Naloxone—ESR1—hematologic cancer	0.000237	0.0992	CrCbGaD
Buprenorphine—CYP2C9—blood—hematologic cancer	0.000236	0.0171	CbGeAlD
Buprenorphine—ABCG2—lung—hematologic cancer	0.000226	0.0165	CbGeAlD
Buprenorphine—CYP2C8—testis—hematologic cancer	0.000219	0.016	CbGeAlD
Buprenorphine—CYP1A2—lung—hematologic cancer	0.000218	0.0158	CbGeAlD
Buprenorphine—ABCG2—testis—hematologic cancer	0.000213	0.0155	CbGeAlD
Buprenorphine—CYP3A5—lung—hematologic cancer	0.00021	0.0153	CbGeAlD
Buprenorphine—ABCB1—hematopoietic system—hematologic cancer	0.000192	0.014	CbGeAlD
Buprenorphine—CYP3A4—blood—hematologic cancer	0.00018	0.0131	CbGeAlD
Buprenorphine—CYP2D6—blood—hematologic cancer	0.000177	0.0129	CbGeAlD
Buprenorphine—ABCG2—lymph node—hematologic cancer	0.000155	0.0113	CbGeAlD
Buprenorphine—CYP2D6—testis—hematologic cancer	0.000146	0.0106	CbGeAlD
Buprenorphine—ABCB1—gonad—hematologic cancer	0.000146	0.0106	CbGeAlD
Buprenorphine—Naltrexone—ABCB1—hematologic cancer	0.000138	0.0577	CrCbGaD
Buprenorphine—ABCB1—blood—hematologic cancer	0.000127	0.00926	CbGeAlD
Buprenorphine—ABCB1—bone marrow—hematologic cancer	0.000123	0.00896	CbGeAlD
Buprenorphine—ABCB1—lung—hematologic cancer	0.000112	0.00811	CbGeAlD
Buprenorphine—Naloxone—ALB—hematologic cancer	0.000106	0.0441	CrCbGaD
Buprenorphine—ABCB1—testis—hematologic cancer	0.000105	0.00766	CbGeAlD
Buprenorphine—Naloxone—ABCB1—hematologic cancer	0.000101	0.0421	CrCbGaD
Buprenorphine—ABCB1—lymph node—hematologic cancer	7.63e-05	0.00555	CbGeAlD
Buprenorphine—Malnutrition—Epirubicin—hematologic cancer	1.65e-05	9.1e-05	CcSEcCtD
Buprenorphine—Diarrhoea—Etoposide—hematologic cancer	1.65e-05	9.07e-05	CcSEcCtD
Buprenorphine—Anorexia—Prednisone—hematologic cancer	1.65e-05	9.05e-05	CcSEcCtD
Buprenorphine—Eye disorder—Doxorubicin—hematologic cancer	1.64e-05	9.04e-05	CcSEcCtD
Buprenorphine—Ill-defined disorder—Methotrexate—hematologic cancer	1.64e-05	9.02e-05	CcSEcCtD
Buprenorphine—Tinnitus—Doxorubicin—hematologic cancer	1.64e-05	9.02e-05	CcSEcCtD
Buprenorphine—Feeling abnormal—Dexamethasone—hematologic cancer	1.63e-05	8.99e-05	CcSEcCtD
Buprenorphine—Feeling abnormal—Betamethasone—hematologic cancer	1.63e-05	8.99e-05	CcSEcCtD
Buprenorphine—Cardiac disorder—Doxorubicin—hematologic cancer	1.63e-05	8.98e-05	CcSEcCtD
Buprenorphine—Flushing—Doxorubicin—hematologic cancer	1.63e-05	8.98e-05	CcSEcCtD
Buprenorphine—Flatulence—Epirubicin—hematologic cancer	1.63e-05	8.97e-05	CcSEcCtD
Buprenorphine—Tension—Epirubicin—hematologic cancer	1.62e-05	8.93e-05	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.62e-05	8.92e-05	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Betamethasone—hematologic cancer	1.62e-05	8.92e-05	CcSEcCtD
Buprenorphine—Dysgeusia—Epirubicin—hematologic cancer	1.62e-05	8.91e-05	CcSEcCtD
Buprenorphine—Hypersensitivity—Triamcinolone—hematologic cancer	1.61e-05	8.86e-05	CcSEcCtD
Buprenorphine—Nervousness—Epirubicin—hematologic cancer	1.61e-05	8.84e-05	CcSEcCtD
Buprenorphine—Back pain—Epirubicin—hematologic cancer	1.6e-05	8.8e-05	CcSEcCtD
Buprenorphine—Angiopathy—Doxorubicin—hematologic cancer	1.6e-05	8.78e-05	CcSEcCtD
Buprenorphine—Malaise—Methotrexate—hematologic cancer	1.59e-05	8.77e-05	CcSEcCtD
Buprenorphine—Dizziness—Etoposide—hematologic cancer	1.59e-05	8.76e-05	CcSEcCtD
Buprenorphine—Muscle spasms—Epirubicin—hematologic cancer	1.59e-05	8.75e-05	CcSEcCtD
Buprenorphine—Immune system disorder—Doxorubicin—hematologic cancer	1.59e-05	8.74e-05	CcSEcCtD
Buprenorphine—Vertigo—Methotrexate—hematologic cancer	1.59e-05	8.74e-05	CcSEcCtD
Buprenorphine—Mediastinal disorder—Doxorubicin—hematologic cancer	1.58e-05	8.72e-05	CcSEcCtD
Buprenorphine—Chills—Doxorubicin—hematologic cancer	1.58e-05	8.68e-05	CcSEcCtD
Buprenorphine—Urticaria—Betamethasone—hematologic cancer	1.57e-05	8.66e-05	CcSEcCtD
Buprenorphine—Urticaria—Dexamethasone—hematologic cancer	1.57e-05	8.66e-05	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.57e-05	8.65e-05	CcSEcCtD
Buprenorphine—Dizziness—Prednisolone—hematologic cancer	1.57e-05	8.64e-05	CcSEcCtD
Buprenorphine—Asthenia—Triamcinolone—hematologic cancer	1.57e-05	8.62e-05	CcSEcCtD
Buprenorphine—Body temperature increased—Betamethasone—hematologic cancer	1.57e-05	8.62e-05	CcSEcCtD
Buprenorphine—Abdominal pain—Dexamethasone—hematologic cancer	1.57e-05	8.62e-05	CcSEcCtD
Buprenorphine—Abdominal pain—Betamethasone—hematologic cancer	1.57e-05	8.62e-05	CcSEcCtD
Buprenorphine—Body temperature increased—Dexamethasone—hematologic cancer	1.57e-05	8.62e-05	CcSEcCtD
Buprenorphine—Nausea—Cisplatin—hematologic cancer	1.56e-05	8.59e-05	CcSEcCtD
Buprenorphine—Insomnia—Prednisone—hematologic cancer	1.56e-05	8.59e-05	CcSEcCtD
Buprenorphine—Vision blurred—Epirubicin—hematologic cancer	1.56e-05	8.58e-05	CcSEcCtD
Buprenorphine—Paraesthesia—Prednisone—hematologic cancer	1.55e-05	8.53e-05	CcSEcCtD
Buprenorphine—Pruritus—Triamcinolone—hematologic cancer	1.55e-05	8.5e-05	CcSEcCtD
Buprenorphine—Cough—Methotrexate—hematologic cancer	1.54e-05	8.49e-05	CcSEcCtD
Buprenorphine—Mental disorder—Doxorubicin—hematologic cancer	1.54e-05	8.48e-05	CcSEcCtD
Buprenorphine—Ill-defined disorder—Epirubicin—hematologic cancer	1.54e-05	8.45e-05	CcSEcCtD
Buprenorphine—Convulsion—Methotrexate—hematologic cancer	1.53e-05	8.43e-05	CcSEcCtD
Buprenorphine—Vomiting—Etoposide—hematologic cancer	1.53e-05	8.43e-05	CcSEcCtD
Buprenorphine—Malnutrition—Doxorubicin—hematologic cancer	1.53e-05	8.42e-05	CcSEcCtD
Buprenorphine—Erythema—Doxorubicin—hematologic cancer	1.53e-05	8.42e-05	CcSEcCtD
Buprenorphine—Agitation—Epirubicin—hematologic cancer	1.52e-05	8.36e-05	CcSEcCtD
Buprenorphine—Dyspepsia—Prednisone—hematologic cancer	1.52e-05	8.36e-05	CcSEcCtD
Buprenorphine—Rash—Etoposide—hematologic cancer	1.52e-05	8.36e-05	CcSEcCtD
Buprenorphine—Dermatitis—Etoposide—hematologic cancer	1.52e-05	8.35e-05	CcSEcCtD
Buprenorphine—Headache—Etoposide—hematologic cancer	1.51e-05	8.3e-05	CcSEcCtD
Buprenorphine—Flatulence—Doxorubicin—hematologic cancer	1.51e-05	8.3e-05	CcSEcCtD
Buprenorphine—Myalgia—Methotrexate—hematologic cancer	1.51e-05	8.28e-05	CcSEcCtD
Buprenorphine—Chest pain—Methotrexate—hematologic cancer	1.51e-05	8.28e-05	CcSEcCtD
Buprenorphine—Arthralgia—Methotrexate—hematologic cancer	1.51e-05	8.28e-05	CcSEcCtD
Buprenorphine—Tension—Doxorubicin—hematologic cancer	1.5e-05	8.26e-05	CcSEcCtD
Buprenorphine—Decreased appetite—Prednisone—hematologic cancer	1.5e-05	8.26e-05	CcSEcCtD
Buprenorphine—Dysgeusia—Doxorubicin—hematologic cancer	1.5e-05	8.25e-05	CcSEcCtD
Buprenorphine—Rash—Prednisolone—hematologic cancer	1.5e-05	8.24e-05	CcSEcCtD
Buprenorphine—Dermatitis—Prednisolone—hematologic cancer	1.5e-05	8.23e-05	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.49e-05	8.22e-05	CcSEcCtD
Buprenorphine—Malaise—Epirubicin—hematologic cancer	1.49e-05	8.21e-05	CcSEcCtD
Buprenorphine—Fatigue—Prednisone—hematologic cancer	1.49e-05	8.19e-05	CcSEcCtD
Buprenorphine—Headache—Prednisolone—hematologic cancer	1.49e-05	8.19e-05	CcSEcCtD
Buprenorphine—Discomfort—Methotrexate—hematologic cancer	1.49e-05	8.18e-05	CcSEcCtD
Buprenorphine—Nervousness—Doxorubicin—hematologic cancer	1.49e-05	8.18e-05	CcSEcCtD
Buprenorphine—Vertigo—Epirubicin—hematologic cancer	1.49e-05	8.18e-05	CcSEcCtD
Buprenorphine—Syncope—Epirubicin—hematologic cancer	1.48e-05	8.16e-05	CcSEcCtD
Buprenorphine—Back pain—Doxorubicin—hematologic cancer	1.48e-05	8.15e-05	CcSEcCtD
Buprenorphine—Constipation—Prednisone—hematologic cancer	1.48e-05	8.12e-05	CcSEcCtD
Buprenorphine—Muscle spasms—Doxorubicin—hematologic cancer	1.47e-05	8.1e-05	CcSEcCtD
Buprenorphine—Palpitations—Epirubicin—hematologic cancer	1.46e-05	8.04e-05	CcSEcCtD
Buprenorphine—Confusional state—Methotrexate—hematologic cancer	1.45e-05	8e-05	CcSEcCtD
Buprenorphine—Loss of consciousness—Epirubicin—hematologic cancer	1.45e-05	8e-05	CcSEcCtD
Buprenorphine—Dizziness—Triamcinolone—hematologic cancer	1.44e-05	7.95e-05	CcSEcCtD
Buprenorphine—Cough—Epirubicin—hematologic cancer	1.44e-05	7.94e-05	CcSEcCtD
Buprenorphine—Anaphylactic shock—Methotrexate—hematologic cancer	1.44e-05	7.94e-05	CcSEcCtD
Buprenorphine—Vision blurred—Doxorubicin—hematologic cancer	1.44e-05	7.94e-05	CcSEcCtD
Buprenorphine—Convulsion—Epirubicin—hematologic cancer	1.43e-05	7.89e-05	CcSEcCtD
Buprenorphine—Infection—Methotrexate—hematologic cancer	1.43e-05	7.89e-05	CcSEcCtD
Buprenorphine—Nausea—Etoposide—hematologic cancer	1.43e-05	7.87e-05	CcSEcCtD
Buprenorphine—Hypertension—Epirubicin—hematologic cancer	1.43e-05	7.86e-05	CcSEcCtD
Buprenorphine—Feeling abnormal—Prednisone—hematologic cancer	1.42e-05	7.83e-05	CcSEcCtD
Buprenorphine—Asthenia—Betamethasone—hematologic cancer	1.42e-05	7.82e-05	CcSEcCtD
Buprenorphine—Asthenia—Dexamethasone—hematologic cancer	1.42e-05	7.82e-05	CcSEcCtD
Buprenorphine—Ill-defined disorder—Doxorubicin—hematologic cancer	1.42e-05	7.81e-05	CcSEcCtD
Buprenorphine—Nervous system disorder—Methotrexate—hematologic cancer	1.42e-05	7.78e-05	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Prednisone—hematologic cancer	1.41e-05	7.77e-05	CcSEcCtD
Buprenorphine—Nausea—Prednisolone—hematologic cancer	1.41e-05	7.76e-05	CcSEcCtD
Buprenorphine—Chest pain—Epirubicin—hematologic cancer	1.41e-05	7.75e-05	CcSEcCtD
Buprenorphine—Arthralgia—Epirubicin—hematologic cancer	1.41e-05	7.75e-05	CcSEcCtD
Buprenorphine—Myalgia—Epirubicin—hematologic cancer	1.41e-05	7.75e-05	CcSEcCtD
Buprenorphine—Agitation—Doxorubicin—hematologic cancer	1.41e-05	7.74e-05	CcSEcCtD
Buprenorphine—Anxiety—Epirubicin—hematologic cancer	1.4e-05	7.72e-05	CcSEcCtD
Buprenorphine—Pruritus—Dexamethasone—hematologic cancer	1.4e-05	7.72e-05	CcSEcCtD
Buprenorphine—Pruritus—Betamethasone—hematologic cancer	1.4e-05	7.72e-05	CcSEcCtD
Buprenorphine—Skin disorder—Methotrexate—hematologic cancer	1.4e-05	7.71e-05	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.4e-05	7.7e-05	CcSEcCtD
Buprenorphine—Hyperhidrosis—Methotrexate—hematologic cancer	1.39e-05	7.67e-05	CcSEcCtD
Buprenorphine—Discomfort—Epirubicin—hematologic cancer	1.39e-05	7.66e-05	CcSEcCtD
Buprenorphine—Vomiting—Triamcinolone—hematologic cancer	1.39e-05	7.64e-05	CcSEcCtD
Buprenorphine—Malaise—Doxorubicin—hematologic cancer	1.38e-05	7.59e-05	CcSEcCtD
Buprenorphine—Rash—Triamcinolone—hematologic cancer	1.38e-05	7.58e-05	CcSEcCtD
Buprenorphine—Dry mouth—Epirubicin—hematologic cancer	1.38e-05	7.58e-05	CcSEcCtD
Buprenorphine—Dermatitis—Triamcinolone—hematologic cancer	1.38e-05	7.57e-05	CcSEcCtD
Buprenorphine—Vertigo—Doxorubicin—hematologic cancer	1.38e-05	7.57e-05	CcSEcCtD
Buprenorphine—Anorexia—Methotrexate—hematologic cancer	1.38e-05	7.57e-05	CcSEcCtD
Buprenorphine—Syncope—Doxorubicin—hematologic cancer	1.37e-05	7.55e-05	CcSEcCtD
Buprenorphine—Urticaria—Prednisone—hematologic cancer	1.37e-05	7.55e-05	CcSEcCtD
Buprenorphine—Headache—Triamcinolone—hematologic cancer	1.37e-05	7.53e-05	CcSEcCtD
Buprenorphine—Abdominal pain—Prednisone—hematologic cancer	1.36e-05	7.51e-05	CcSEcCtD
Buprenorphine—Body temperature increased—Prednisone—hematologic cancer	1.36e-05	7.51e-05	CcSEcCtD
Buprenorphine—Confusional state—Epirubicin—hematologic cancer	1.36e-05	7.49e-05	CcSEcCtD
Buprenorphine—Diarrhoea—Dexamethasone—hematologic cancer	1.36e-05	7.46e-05	CcSEcCtD
Buprenorphine—Diarrhoea—Betamethasone—hematologic cancer	1.36e-05	7.46e-05	CcSEcCtD
Buprenorphine—Palpitations—Doxorubicin—hematologic cancer	1.35e-05	7.44e-05	CcSEcCtD
Buprenorphine—Anaphylactic shock—Epirubicin—hematologic cancer	1.35e-05	7.43e-05	CcSEcCtD
Buprenorphine—Oedema—Epirubicin—hematologic cancer	1.35e-05	7.43e-05	CcSEcCtD
Buprenorphine—Hypotension—Methotrexate—hematologic cancer	1.35e-05	7.42e-05	CcSEcCtD
Buprenorphine—Loss of consciousness—Doxorubicin—hematologic cancer	1.35e-05	7.4e-05	CcSEcCtD
Buprenorphine—Infection—Epirubicin—hematologic cancer	1.34e-05	7.38e-05	CcSEcCtD
Buprenorphine—Cough—Doxorubicin—hematologic cancer	1.34e-05	7.35e-05	CcSEcCtD
Buprenorphine—Shock—Epirubicin—hematologic cancer	1.33e-05	7.31e-05	CcSEcCtD
Buprenorphine—Convulsion—Doxorubicin—hematologic cancer	1.33e-05	7.3e-05	CcSEcCtD
Buprenorphine—Nervous system disorder—Epirubicin—hematologic cancer	1.32e-05	7.28e-05	CcSEcCtD
Buprenorphine—Hypertension—Doxorubicin—hematologic cancer	1.32e-05	7.27e-05	CcSEcCtD
Buprenorphine—Tachycardia—Epirubicin—hematologic cancer	1.32e-05	7.25e-05	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.31e-05	7.23e-05	CcSEcCtD
Buprenorphine—Skin disorder—Epirubicin—hematologic cancer	1.31e-05	7.22e-05	CcSEcCtD
Buprenorphine—Dizziness—Betamethasone—hematologic cancer	1.31e-05	7.21e-05	CcSEcCtD
Buprenorphine—Dizziness—Dexamethasone—hematologic cancer	1.31e-05	7.21e-05	CcSEcCtD
Buprenorphine—Hyperhidrosis—Epirubicin—hematologic cancer	1.31e-05	7.18e-05	CcSEcCtD
Buprenorphine—Insomnia—Methotrexate—hematologic cancer	1.31e-05	7.18e-05	CcSEcCtD
Buprenorphine—Arthralgia—Doxorubicin—hematologic cancer	1.3e-05	7.17e-05	CcSEcCtD
Buprenorphine—Myalgia—Doxorubicin—hematologic cancer	1.3e-05	7.17e-05	CcSEcCtD
Buprenorphine—Chest pain—Doxorubicin—hematologic cancer	1.3e-05	7.17e-05	CcSEcCtD
Buprenorphine—Anxiety—Doxorubicin—hematologic cancer	1.3e-05	7.15e-05	CcSEcCtD
Buprenorphine—Nausea—Triamcinolone—hematologic cancer	1.3e-05	7.14e-05	CcSEcCtD
Buprenorphine—Paraesthesia—Methotrexate—hematologic cancer	1.3e-05	7.13e-05	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.29e-05	7.12e-05	CcSEcCtD
Buprenorphine—Discomfort—Doxorubicin—hematologic cancer	1.29e-05	7.08e-05	CcSEcCtD
Buprenorphine—Anorexia—Epirubicin—hematologic cancer	1.29e-05	7.08e-05	CcSEcCtD
Buprenorphine—Dyspnoea—Methotrexate—hematologic cancer	1.29e-05	7.08e-05	CcSEcCtD
Buprenorphine—Somnolence—Methotrexate—hematologic cancer	1.28e-05	7.06e-05	CcSEcCtD
Buprenorphine—Dry mouth—Doxorubicin—hematologic cancer	1.27e-05	7.01e-05	CcSEcCtD
Buprenorphine—Hypersensitivity—Prednisone—hematologic cancer	1.27e-05	7e-05	CcSEcCtD
Buprenorphine—Dyspepsia—Methotrexate—hematologic cancer	1.27e-05	6.99e-05	CcSEcCtD
Buprenorphine—Hypotension—Epirubicin—hematologic cancer	1.26e-05	6.94e-05	CcSEcCtD
Buprenorphine—Vomiting—Betamethasone—hematologic cancer	1.26e-05	6.93e-05	CcSEcCtD
Buprenorphine—Vomiting—Dexamethasone—hematologic cancer	1.26e-05	6.93e-05	CcSEcCtD
Buprenorphine—Confusional state—Doxorubicin—hematologic cancer	1.26e-05	6.93e-05	CcSEcCtD
Buprenorphine—Decreased appetite—Methotrexate—hematologic cancer	1.25e-05	6.9e-05	CcSEcCtD
Buprenorphine—Rash—Dexamethasone—hematologic cancer	1.25e-05	6.88e-05	CcSEcCtD
Buprenorphine—Rash—Betamethasone—hematologic cancer	1.25e-05	6.88e-05	CcSEcCtD
Buprenorphine—Anaphylactic shock—Doxorubicin—hematologic cancer	1.25e-05	6.87e-05	CcSEcCtD
Buprenorphine—Oedema—Doxorubicin—hematologic cancer	1.25e-05	6.87e-05	CcSEcCtD
Buprenorphine—Dermatitis—Betamethasone—hematologic cancer	1.25e-05	6.87e-05	CcSEcCtD
Buprenorphine—Dermatitis—Dexamethasone—hematologic cancer	1.25e-05	6.87e-05	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.25e-05	6.85e-05	CcSEcCtD
Buprenorphine—Fatigue—Methotrexate—hematologic cancer	1.24e-05	6.84e-05	CcSEcCtD
Buprenorphine—Headache—Betamethasone—hematologic cancer	1.24e-05	6.83e-05	CcSEcCtD
Buprenorphine—Headache—Dexamethasone—hematologic cancer	1.24e-05	6.83e-05	CcSEcCtD
Buprenorphine—Infection—Doxorubicin—hematologic cancer	1.24e-05	6.83e-05	CcSEcCtD
Buprenorphine—Asthenia—Prednisone—hematologic cancer	1.24e-05	6.81e-05	CcSEcCtD
Buprenorphine—Pain—Methotrexate—hematologic cancer	1.23e-05	6.79e-05	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.23e-05	6.77e-05	CcSEcCtD
Buprenorphine—Shock—Doxorubicin—hematologic cancer	1.23e-05	6.76e-05	CcSEcCtD
Buprenorphine—Nervous system disorder—Doxorubicin—hematologic cancer	1.23e-05	6.74e-05	CcSEcCtD
Buprenorphine—Pruritus—Prednisone—hematologic cancer	1.22e-05	6.72e-05	CcSEcCtD
Buprenorphine—Insomnia—Epirubicin—hematologic cancer	1.22e-05	6.72e-05	CcSEcCtD
Buprenorphine—Tachycardia—Doxorubicin—hematologic cancer	1.22e-05	6.71e-05	CcSEcCtD
Buprenorphine—Skin disorder—Doxorubicin—hematologic cancer	1.21e-05	6.68e-05	CcSEcCtD
Buprenorphine—Paraesthesia—Epirubicin—hematologic cancer	1.21e-05	6.67e-05	CcSEcCtD
Buprenorphine—Hyperhidrosis—Doxorubicin—hematologic cancer	1.21e-05	6.64e-05	CcSEcCtD
Buprenorphine—Dyspnoea—Epirubicin—hematologic cancer	1.2e-05	6.62e-05	CcSEcCtD
Buprenorphine—Somnolence—Epirubicin—hematologic cancer	1.2e-05	6.6e-05	CcSEcCtD
Buprenorphine—Anorexia—Doxorubicin—hematologic cancer	1.19e-05	6.55e-05	CcSEcCtD
Buprenorphine—Feeling abnormal—Methotrexate—hematologic cancer	1.19e-05	6.54e-05	CcSEcCtD
Buprenorphine—Dyspepsia—Epirubicin—hematologic cancer	1.19e-05	6.54e-05	CcSEcCtD
Buprenorphine—Diarrhoea—Prednisone—hematologic cancer	1.18e-05	6.5e-05	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Methotrexate—hematologic cancer	1.18e-05	6.49e-05	CcSEcCtD
Buprenorphine—Nausea—Dexamethasone—hematologic cancer	1.18e-05	6.48e-05	CcSEcCtD
Buprenorphine—Nausea—Betamethasone—hematologic cancer	1.18e-05	6.48e-05	CcSEcCtD
Buprenorphine—Decreased appetite—Epirubicin—hematologic cancer	1.17e-05	6.46e-05	CcSEcCtD
Buprenorphine—Hypotension—Doxorubicin—hematologic cancer	1.17e-05	6.42e-05	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.17e-05	6.41e-05	CcSEcCtD
Buprenorphine—Fatigue—Epirubicin—hematologic cancer	1.16e-05	6.4e-05	CcSEcCtD
Buprenorphine—Pain—Epirubicin—hematologic cancer	1.15e-05	6.35e-05	CcSEcCtD
Buprenorphine—Constipation—Epirubicin—hematologic cancer	1.15e-05	6.35e-05	CcSEcCtD
Buprenorphine—Urticaria—Methotrexate—hematologic cancer	1.15e-05	6.31e-05	CcSEcCtD
Buprenorphine—Dizziness—Prednisone—hematologic cancer	1.14e-05	6.28e-05	CcSEcCtD
Buprenorphine—Body temperature increased—Methotrexate—hematologic cancer	1.14e-05	6.27e-05	CcSEcCtD
Buprenorphine—Abdominal pain—Methotrexate—hematologic cancer	1.14e-05	6.27e-05	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.14e-05	6.26e-05	CcSEcCtD
Buprenorphine—Insomnia—Doxorubicin—hematologic cancer	1.13e-05	6.22e-05	CcSEcCtD
Buprenorphine—Paraesthesia—Doxorubicin—hematologic cancer	1.12e-05	6.17e-05	CcSEcCtD
Buprenorphine—Dyspnoea—Doxorubicin—hematologic cancer	1.11e-05	6.13e-05	CcSEcCtD
Buprenorphine—Feeling abnormal—Epirubicin—hematologic cancer	1.11e-05	6.12e-05	CcSEcCtD
Buprenorphine—Somnolence—Doxorubicin—hematologic cancer	1.11e-05	6.11e-05	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Epirubicin—hematologic cancer	1.1e-05	6.07e-05	CcSEcCtD
Buprenorphine—Dyspepsia—Doxorubicin—hematologic cancer	1.1e-05	6.05e-05	CcSEcCtD
Buprenorphine—Vomiting—Prednisone—hematologic cancer	1.1e-05	6.04e-05	CcSEcCtD
Buprenorphine—Rash—Prednisone—hematologic cancer	1.09e-05	5.99e-05	CcSEcCtD
Buprenorphine—Dermatitis—Prednisone—hematologic cancer	1.09e-05	5.98e-05	CcSEcCtD
Buprenorphine—Decreased appetite—Doxorubicin—hematologic cancer	1.09e-05	5.97e-05	CcSEcCtD
Buprenorphine—Headache—Prednisone—hematologic cancer	1.08e-05	5.95e-05	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.08e-05	5.93e-05	CcSEcCtD
Buprenorphine—Fatigue—Doxorubicin—hematologic cancer	1.08e-05	5.93e-05	CcSEcCtD
Buprenorphine—Urticaria—Epirubicin—hematologic cancer	1.07e-05	5.9e-05	CcSEcCtD
Buprenorphine—Pain—Doxorubicin—hematologic cancer	1.07e-05	5.88e-05	CcSEcCtD
Buprenorphine—Constipation—Doxorubicin—hematologic cancer	1.07e-05	5.88e-05	CcSEcCtD
Buprenorphine—Body temperature increased—Epirubicin—hematologic cancer	1.07e-05	5.87e-05	CcSEcCtD
Buprenorphine—Abdominal pain—Epirubicin—hematologic cancer	1.07e-05	5.87e-05	CcSEcCtD
Buprenorphine—Hypersensitivity—Methotrexate—hematologic cancer	1.06e-05	5.85e-05	CcSEcCtD
Buprenorphine—Asthenia—Methotrexate—hematologic cancer	1.04e-05	5.7e-05	CcSEcCtD
Buprenorphine—Feeling abnormal—Doxorubicin—hematologic cancer	1.03e-05	5.66e-05	CcSEcCtD
Buprenorphine—Nausea—Prednisone—hematologic cancer	1.03e-05	5.64e-05	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.02e-05	5.62e-05	CcSEcCtD
Buprenorphine—Pruritus—Methotrexate—hematologic cancer	1.02e-05	5.62e-05	CcSEcCtD
Buprenorphine—Hypersensitivity—Epirubicin—hematologic cancer	9.95e-06	5.47e-05	CcSEcCtD
Buprenorphine—Urticaria—Doxorubicin—hematologic cancer	9.93e-06	5.46e-05	CcSEcCtD
Buprenorphine—Body temperature increased—Doxorubicin—hematologic cancer	9.88e-06	5.43e-05	CcSEcCtD
Buprenorphine—Abdominal pain—Doxorubicin—hematologic cancer	9.88e-06	5.43e-05	CcSEcCtD
Buprenorphine—Diarrhoea—Methotrexate—hematologic cancer	9.87e-06	5.43e-05	CcSEcCtD
Buprenorphine—Asthenia—Epirubicin—hematologic cancer	9.69e-06	5.33e-05	CcSEcCtD
Buprenorphine—Pruritus—Epirubicin—hematologic cancer	9.55e-06	5.26e-05	CcSEcCtD
Buprenorphine—Dizziness—Methotrexate—hematologic cancer	9.54e-06	5.25e-05	CcSEcCtD
Buprenorphine—Diarrhoea—Epirubicin—hematologic cancer	9.24e-06	5.08e-05	CcSEcCtD
Buprenorphine—Hypersensitivity—Doxorubicin—hematologic cancer	9.21e-06	5.06e-05	CcSEcCtD
Buprenorphine—Vomiting—Methotrexate—hematologic cancer	9.17e-06	5.05e-05	CcSEcCtD
Buprenorphine—Rash—Methotrexate—hematologic cancer	9.1e-06	5e-05	CcSEcCtD
Buprenorphine—Dermatitis—Methotrexate—hematologic cancer	9.09e-06	5e-05	CcSEcCtD
Buprenorphine—Headache—Methotrexate—hematologic cancer	9.04e-06	4.97e-05	CcSEcCtD
Buprenorphine—Asthenia—Doxorubicin—hematologic cancer	8.96e-06	4.93e-05	CcSEcCtD
Buprenorphine—Dizziness—Epirubicin—hematologic cancer	8.93e-06	4.91e-05	CcSEcCtD
Buprenorphine—Pruritus—Doxorubicin—hematologic cancer	8.84e-06	4.86e-05	CcSEcCtD
Buprenorphine—Vomiting—Epirubicin—hematologic cancer	8.59e-06	4.72e-05	CcSEcCtD
Buprenorphine—Nausea—Methotrexate—hematologic cancer	8.57e-06	4.71e-05	CcSEcCtD
Buprenorphine—Diarrhoea—Doxorubicin—hematologic cancer	8.55e-06	4.7e-05	CcSEcCtD
Buprenorphine—Rash—Epirubicin—hematologic cancer	8.51e-06	4.68e-05	CcSEcCtD
Buprenorphine—Dermatitis—Epirubicin—hematologic cancer	8.51e-06	4.68e-05	CcSEcCtD
Buprenorphine—Headache—Epirubicin—hematologic cancer	8.46e-06	4.65e-05	CcSEcCtD
Buprenorphine—Dizziness—Doxorubicin—hematologic cancer	8.26e-06	4.55e-05	CcSEcCtD
Buprenorphine—Nausea—Epirubicin—hematologic cancer	8.02e-06	4.41e-05	CcSEcCtD
Buprenorphine—Vomiting—Doxorubicin—hematologic cancer	7.94e-06	4.37e-05	CcSEcCtD
Buprenorphine—Rash—Doxorubicin—hematologic cancer	7.88e-06	4.33e-05	CcSEcCtD
Buprenorphine—Dermatitis—Doxorubicin—hematologic cancer	7.87e-06	4.33e-05	CcSEcCtD
Buprenorphine—Headache—Doxorubicin—hematologic cancer	7.83e-06	4.31e-05	CcSEcCtD
Buprenorphine—Nausea—Doxorubicin—hematologic cancer	7.42e-06	4.08e-05	CcSEcCtD
Buprenorphine—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	2.29e-06	3.3e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	2.29e-06	3.29e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AKT1—hematologic cancer	2.28e-06	3.29e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYCS—hematologic cancer	2.28e-06	3.29e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	2.28e-06	3.29e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GSTM1—hematologic cancer	2.27e-06	3.27e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—NCOR1—hematologic cancer	2.27e-06	3.27e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	2.27e-06	3.27e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HRAS—hematologic cancer	2.27e-06	3.27e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC22A1—hematologic cancer	2.26e-06	3.25e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CRABP1—hematologic cancer	2.26e-06	3.25e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3R1—hematologic cancer	2.26e-06	3.25e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—KRAS—hematologic cancer	2.26e-06	3.25e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.24e-06	3.23e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3R1—hematologic cancer	2.24e-06	3.22e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EP300—hematologic cancer	2.23e-06	3.22e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN1B—hematologic cancer	2.23e-06	3.21e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTP1—hematologic cancer	2.21e-06	3.18e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—FGF2—hematologic cancer	2.21e-06	3.18e-05	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AKT1—hematologic cancer	2.21e-06	3.18e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALOX5—hematologic cancer	2.2e-06	3.17e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	2.19e-06	3.15e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CASP3—hematologic cancer	2.19e-06	3.15e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL2—hematologic cancer	2.18e-06	3.14e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3R1—hematologic cancer	2.18e-06	3.13e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CD—hematologic cancer	2.17e-06	3.13e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SRC—hematologic cancer	2.17e-06	3.13e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL6—hematologic cancer	2.17e-06	3.13e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTP1—hematologic cancer	2.15e-06	3.1e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ALB—hematologic cancer	2.14e-06	3.09e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.14e-06	3.08e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NUP98—hematologic cancer	2.13e-06	3.07e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCND1—hematologic cancer	2.13e-06	3.06e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—JUN—hematologic cancer	2.12e-06	3.06e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTEN—hematologic cancer	2.12e-06	3.06e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—hematologic cancer	2.11e-06	3.05e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—JAK2—hematologic cancer	2.11e-06	3.04e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—STAT3—hematologic cancer	2.09e-06	3.02e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ABCB1—hematologic cancer	2.09e-06	3.01e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NRAS—hematologic cancer	2.09e-06	3.01e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CB—hematologic cancer	2.08e-06	3e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—PIK3CA—hematologic cancer	2.07e-06	2.98e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.07e-06	2.98e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.07e-06	2.98e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CB—hematologic cancer	2.07e-06	2.97e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MDM2—hematologic cancer	2.06e-06	2.97e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CD44—hematologic cancer	2.06e-06	2.97e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NQO1—hematologic cancer	2.06e-06	2.97e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN1A—hematologic cancer	2.06e-06	2.96e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NUP214—hematologic cancer	2.06e-06	2.96e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTEN—hematologic cancer	2.05e-06	2.96e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3R1—hematologic cancer	2.05e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.04e-06	2.94e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTP1—hematologic cancer	2.03e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTM1—hematologic cancer	2.03e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—NCOR1—hematologic cancer	2.03e-06	2.92e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—EP300—hematologic cancer	2.02e-06	2.91e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.02e-06	2.91e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—MTR—hematologic cancer	2.01e-06	2.9e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.01e-06	2.9e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTP1—hematologic cancer	2.01e-06	2.9e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—MTHFR—hematologic cancer	2.01e-06	2.89e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK8—hematologic cancer	2.01e-06	2.89e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CB—hematologic cancer	2.01e-06	2.89e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MTOR—hematologic cancer	2.01e-06	2.89e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AKT1—hematologic cancer	2e-06	2.88e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK3—hematologic cancer	2e-06	2.88e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—NCOR1—hematologic cancer	1.98e-06	2.85e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTM1—hematologic cancer	1.98e-06	2.85e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ENO2—hematologic cancer	1.97e-06	2.84e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EP300—hematologic cancer	1.96e-06	2.82e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYCS—hematologic cancer	1.95e-06	2.81e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CG—hematologic cancer	1.95e-06	2.81e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.95e-06	2.8e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MYC—hematologic cancer	1.95e-06	2.8e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TGFB1—hematologic cancer	1.94e-06	2.8e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	1.94e-06	2.79e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ABCB1—hematologic cancer	1.92e-06	2.77e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HRAS—hematologic cancer	1.92e-06	2.76e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTT1—hematologic cancer	1.92e-06	2.76e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ABCB1—hematologic cancer	1.91e-06	2.74e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SRC—hematologic cancer	1.9e-06	2.74e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3CA—hematologic cancer	1.89e-06	2.73e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CB—hematologic cancer	1.89e-06	2.73e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1B—hematologic cancer	1.88e-06	2.71e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SDC1—hematologic cancer	1.87e-06	2.7e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—NCOR1—hematologic cancer	1.87e-06	2.69e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTM1—hematologic cancer	1.87e-06	2.69e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AKT1—hematologic cancer	1.86e-06	2.68e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—hematologic cancer	1.85e-06	2.67e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—NCOR1—hematologic cancer	1.85e-06	2.66e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTM1—hematologic cancer	1.85e-06	2.66e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CASP3—hematologic cancer	1.85e-06	2.66e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL2—hematologic cancer	1.84e-06	2.66e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—STAT3—hematologic cancer	1.84e-06	2.64e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL6—hematologic cancer	1.83e-06	2.64e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NRAS—hematologic cancer	1.83e-06	2.64e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CREBBP—hematologic cancer	1.81e-06	2.6e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTEN—hematologic cancer	1.8e-06	2.59e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KRAS—hematologic cancer	1.8e-06	2.59e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCND1—hematologic cancer	1.8e-06	2.59e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—JUN—hematologic cancer	1.79e-06	2.58e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—MTHFR—hematologic cancer	1.79e-06	2.58e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTEN—hematologic cancer	1.78e-06	2.57e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.77e-06	2.55e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK3—hematologic cancer	1.75e-06	2.53e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—MTHFR—hematologic cancer	1.75e-06	2.52e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.75e-06	2.51e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1A—hematologic cancer	1.74e-06	2.5e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTEN—hematologic cancer	1.74e-06	2.5e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTP1—hematologic cancer	1.72e-06	2.48e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—EP300—hematologic cancer	1.72e-06	2.47e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CD—hematologic cancer	1.71e-06	2.47e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MYC—hematologic cancer	1.71e-06	2.46e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—EP300—hematologic cancer	1.7e-06	2.45e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TGFB1—hematologic cancer	1.7e-06	2.45e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK8—hematologic cancer	1.7e-06	2.44e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AKT1—hematologic cancer	1.69e-06	2.44e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ALB—hematologic cancer	1.69e-06	2.44e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CG—hematologic cancer	1.69e-06	2.43e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.66e-06	2.4e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EP300—hematologic cancer	1.65e-06	2.38e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CA—hematologic cancer	1.65e-06	2.38e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—MTHFR—hematologic cancer	1.65e-06	2.37e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTEN—hematologic cancer	1.64e-06	2.36e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—MTHFR—hematologic cancer	1.63e-06	2.35e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ABCB1—hematologic cancer	1.63e-06	2.34e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3R1—hematologic cancer	1.62e-06	2.33e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SRC—hematologic cancer	1.61e-06	2.32e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—hematologic cancer	1.6e-06	2.3e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NQO1—hematologic cancer	1.59e-06	2.29e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CD44—hematologic cancer	1.59e-06	2.29e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NCOR1—hematologic cancer	1.58e-06	2.28e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTM1—hematologic cancer	1.58e-06	2.28e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.58e-06	2.28e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KRAS—hematologic cancer	1.58e-06	2.27e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—hematologic cancer	1.57e-06	2.26e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CREBBP—hematologic cancer	1.56e-06	2.25e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—EP300—hematologic cancer	1.56e-06	2.25e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STAT3—hematologic cancer	1.55e-06	2.23e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NRAS—hematologic cancer	1.55e-06	2.23e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AKT1—hematologic cancer	1.55e-06	2.23e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HRAS—hematologic cancer	1.53e-06	2.2e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.51e-06	2.17e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYCS—hematologic cancer	1.51e-06	2.17e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CA—hematologic cancer	1.5e-06	2.16e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.5e-06	2.16e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CB—hematologic cancer	1.49e-06	2.15e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CD—hematologic cancer	1.48e-06	2.14e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK3—hematologic cancer	1.48e-06	2.14e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.47e-06	2.12e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ALB—hematologic cancer	1.46e-06	2.11e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL6—hematologic cancer	1.46e-06	2.11e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CA—hematologic cancer	1.45e-06	2.09e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MYC—hematologic cancer	1.44e-06	2.08e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.44e-06	2.07e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TGFB1—hematologic cancer	1.44e-06	2.07e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—hematologic cancer	1.4e-06	2.02e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3R1—hematologic cancer	1.4e-06	2.02e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.4e-06	2.01e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.4e-06	2.01e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.39e-06	2e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.37e-06	1.98e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CREBBP—hematologic cancer	1.36e-06	1.96e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AKT1—hematologic cancer	1.35e-06	1.94e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HRAS—hematologic cancer	1.34e-06	1.93e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KRAS—hematologic cancer	1.33e-06	1.92e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.33e-06	1.91e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CD—hematologic cancer	1.32e-06	1.91e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ALB—hematologic cancer	1.31e-06	1.88e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CB—hematologic cancer	1.29e-06	1.86e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.29e-06	1.86e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTEN—hematologic cancer	1.29e-06	1.86e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.28e-06	1.85e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL6—hematologic cancer	1.28e-06	1.85e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ALB—hematologic cancer	1.28e-06	1.84e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.27e-06	1.83e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CA—hematologic cancer	1.27e-06	1.83e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CA—hematologic cancer	1.26e-06	1.81e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.26e-06	1.81e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.25e-06	1.8e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.23e-06	1.77e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—EP300—hematologic cancer	1.23e-06	1.77e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CA—hematologic cancer	1.22e-06	1.76e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AKT1—hematologic cancer	1.22e-06	1.76e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.22e-06	1.76e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.22e-06	1.76e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.22e-06	1.76e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.22e-06	1.75e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.21e-06	1.74e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ALB—hematologic cancer	1.2e-06	1.73e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ALB—hematologic cancer	1.19e-06	1.72e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—hematologic cancer	1.18e-06	1.71e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AKT1—hematologic cancer	1.18e-06	1.7e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.17e-06	1.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.15e-06	1.66e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CA—hematologic cancer	1.15e-06	1.66e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.15e-06	1.66e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.14e-06	1.64e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HRAS—hematologic cancer	1.13e-06	1.63e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.13e-06	1.62e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTEN—hematologic cancer	1.12e-06	1.61e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.09e-06	1.57e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6—hematologic cancer	1.08e-06	1.56e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.08e-06	1.55e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—EP300—hematologic cancer	1.07e-06	1.53e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.06e-06	1.53e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.05e-06	1.52e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AKT1—hematologic cancer	1.04e-06	1.49e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.03e-06	1.49e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AKT1—hematologic cancer	1.03e-06	1.48e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ALB—hematologic cancer	1.02e-06	1.47e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AKT1—hematologic cancer	1e-06	1.44e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTEN—hematologic cancer	9.97e-07	1.44e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	9.74e-07	1.4e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTEN—hematologic cancer	9.74e-07	1.4e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—EP300—hematologic cancer	9.51e-07	1.37e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AKT1—hematologic cancer	9.43e-07	1.36e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—EP300—hematologic cancer	9.28e-07	1.34e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTEN—hematologic cancer	9.17e-07	1.32e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CA—hematologic cancer	9.1e-07	1.31e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTEN—hematologic cancer	9.09e-07	1.31e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	9.06e-07	1.3e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	8.99e-07	1.3e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—EP300—hematologic cancer	8.75e-07	1.26e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—EP300—hematologic cancer	8.67e-07	1.25e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CREBBP—hematologic cancer	8.4e-07	1.21e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	7.96e-07	1.15e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CA—hematologic cancer	7.88e-07	1.14e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALB—hematologic cancer	7.86e-07	1.13e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTEN—hematologic cancer	7.77e-07	1.12e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	7.52e-07	1.08e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKT1—hematologic cancer	7.44e-07	1.07e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—EP300—hematologic cancer	7.41e-07	1.07e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CA—hematologic cancer	7.04e-07	1.01e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	6.94e-07	1e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CA—hematologic cancer	6.87e-07	9.89e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	6.47e-07	9.32e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKT1—hematologic cancer	6.44e-07	9.27e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CA—hematologic cancer	6.42e-07	9.24e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTEN—hematologic cancer	6e-07	8.64e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKT1—hematologic cancer	5.75e-07	8.28e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—EP300—hematologic cancer	5.72e-07	8.24e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKT1—hematologic cancer	5.61e-07	8.08e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	5.48e-07	7.9e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKT1—hematologic cancer	5.29e-07	7.61e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKT1—hematologic cancer	5.24e-07	7.55e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKT1—hematologic cancer	4.48e-07	6.45e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	4.23e-07	6.09e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKT1—hematologic cancer	3.46e-07	4.98e-06	CbGpPWpGaD
